Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Oxford BioDynamics ( (GB:OBD) ) is now available.
Oxford BioDynamics Plc announced that the recent UK National Screening Committee’s draft recommendation on prostate cancer screening does not directly affect its EpiSwitch PSE test. Despite this, the company has reported six consecutive months of record sales for the PSE test in the US and private healthcare in the UK, indicating strong market performance and growth potential.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Underperform.
Oxford BioDynamics’ stock score is primarily impacted by its challenging financial performance, characterized by consistent losses and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to a negative P/E ratio. These factors collectively suggest a high-risk investment with significant financial and operational challenges.
To see Spark’s full report on GB:OBD stock, click here.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company focused on advancing personalized healthcare through precision clinical diagnostic tests for life-changing diseases. The company offers two main products: the EpiSwitch® PSE (Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test), both of which are based on its proprietary 3D genomic biomarker platform, EpiSwitch®. These tests enhance the predictive accuracy of existing medical tests and are used in various fields including oncology, neurology, and more. The company operates from its headquarters in Oxford, UK, with additional facilities in the US and Malaysia, and is listed on the London Stock Exchange’s AIM.
Average Trading Volume: 31,460,036
Technical Sentiment Signal: Strong Sell
Current Market Cap: £12.87M
For a thorough assessment of OBD stock, go to TipRanks’ Stock Analysis page.